Godse Kiran
Department of Dermatology, D Y Patil University School of Medicine, Navi Mumbai, Maharashtra, India.
Indian J Dermatol. 2017 Mar-Apr;62(2):195-199. doi: 10.4103/ijd.IJD_233_16.
Psoriasis is a complex inflammatory disease that occurs in genetically susceptible individuals and presents with the development of erythematous scaly plaques on the skin. Interleukins (ILs) in the Th17 pathway play a pivotal role in the pathogenesis of psoriasis and have thus become targets for recent biologic drug development. Secukinumab is a human monoclonal IgG1k antibody that has been developed to target and block the actions of IL-17A. Secukinumab recently approved for use as first-line systemic therapy in a patient with moderate to severe psoriasis has been studied first in psoriasis before other diseases. Both Phase II and III clinical trials have demonstrated the effectiveness of secukinumab in the treatment of moderate-to-severe plaque psoriasis, and it has demonstrated superiority to other comparable biologics on the market, including the tumor necrosis factor inhibitor etanercept. Secukinumab has also shown superiority to ustekinumab, a relatively recent biologic introduced for the treatment of psoriasis. Besides demonstrating better efficacy compared to etanercept and ustekinumab, secukinumab has also demonstrated a greater impact of the quality of life of patients with a comparable safety profile. Secukinumab shows great promise in having a tremendous impact on the treatment of plaque psoriasis based on its ability to produce similar, if not better, clinical outcomes than other biologic antipsoriasis medications.
银屑病是一种复杂的炎症性疾病，发生于遗传易感个体，表现为皮肤上出现红斑鳞屑性斑块。Th17途径中的白细胞介素（ILs）在银屑病发病机制中起关键作用，因此成为近期生物药物研发的靶点。司库奇尤单抗是一种人源化单克隆IgG1k抗体，旨在靶向并阻断IL-17A的作用。司库奇尤单抗最近被批准用于中重度银屑病患者的一线全身治疗，它在银屑病领域的研究先于其他疾病。II期和III期临床试验均已证明司库奇尤单抗治疗中重度斑块状银屑病的有效性，并且它已显示出优于市场上其他同类生物制剂，包括肿瘤坏死因子抑制剂依那西普。司库奇尤单抗还显示出优于乌司奴单抗，乌司奴单抗是一种相对较新的用于治疗银屑病的生物制剂。除了与依那西普和乌司奴单抗相比疗效更好外，司库奇尤单抗在安全性相当的情况下，对患者生活质量的影响也更大。基于其产生与其他生物抗银屑病药物相似（甚至更好）的临床疗效的能力，司库奇尤单抗在斑块状银屑病治疗方面显示出巨大的前景。
